Triple Agonist vs Dual Agonist Weight Loss: What the 2026 Trials Really Show

Triple agonist vs dual agonist weight loss comes down to this: the leading triple agonist did lose more weight in trials than the leading dual agonist — but by about 3 to 6 percentage points, not the 7 to 9 you've seen in headlines. And no triple agonist for weight management is approved anywhere in the world. Tirzepatide is the one you can get by prescription today in the United States.

Here's the part almost nobody tells you.

We put five drugs across six trial arms on one measuring stick. Two of them hit the exact same two receptors as each other — same category, same targets — and they came in 7.6 points apart. That's more than twice the 3.3-point gap between the best triple and the best dual on our strictest matched ruler.

One "dual agonist" even finished below a single-agonist drug.

So counting receptors doesn't tell you what you think it tells you. We'll show you the numbers, show you where our own math gets shaky, and give you the one date that will actually settle this.

Best for you if

• You saw a "30% weight loss" headline and want to know if it's real
• You're deciding between starting Zepbound now or holding out for something stronger
• You want to understand the trial numbers instead of just being handed a winner
• You keep seeing "triple agonist" and "GLP-3" and want a straight explanation

Not for you if

• You're looking for a place to buy retatrutide. We don't help with that, and we explain why below
• You want a chart to convert your tirzepatide dose into a retatrutide dose. No such chart exists
• You need a diagnosis or a prescribing decision — that's your clinician's job, not a webpage's

---

The 30-second answer

Sources: Eli Lilly TRIUMPH-1 topline (May 21, 2026); SURMOUNT-1 published results; Zepbound US prescribing information. Two separate trials — not a head-to-head comparison.

---

The RX Index is the independent GLP-1 decision resource that scores telehealth providers and treatment paths on clinical legitimacy, care quality, transparency, access, and cost, so readers can choose the path that fits their situation.

What we actually verified for this page

Prices and provider details are checked separately and carry their own dates.

---

Before you read the numbers: this doesn't decide it for you

The right GLP-1 provider isn't the same for everyone — it depends on your state, your insurance and formulary, whether you want an FDA-approved medication or a compounded option that is not FDA-approved, your preferred treatment path (injection or oral), and your budget. Because a general answer can't resolve those for you, use The RX Index's Find My GLP-1 Path tool to get a personalized provider match with source-verified pricing before you choose.

→ See which GLP-1 treatment paths fit your situation — free, about 2 minutes, no signup.

---

What is the difference between a triple agonist and a dual agonist?

A dual agonist is a drug that switches on two hormone receptors. A triple agonist switches on three. Tirzepatide, sold as Zepbound and Mounjaro, activates the GIP and GLP-1 receptors. Retatrutide adds a third — the glucagon receptor. Activating more receptors does not automatically mean more weight loss.

Think of your body as having a few different switches that affect hunger and how you burn energy. These drugs are keys. Some keys turn two switches. Some turn three.

Here's what each switch does, in plain terms.

GLP-1 — the "I'm full" switch

GLP-1 is a hormone your gut makes after you eat. It tells your brain you've had enough. It also slows how fast food leaves your stomach, so you stay full longer.

Every drug on this page turns this switch. Semaglutide (Ozempic, Wegovy) turns only this one.

GIP — the helper switch

GIP is a second gut hormone. On its own it's less famous. Paired with GLP-1, it seems to add something — and preclinical research suggests GIP activity may also calm nausea and vomiting signaling, which could help people stay on the drug long enough to work.

Tirzepatide turns this switch plus GLP-1. That's what makes it a dual agonist.

Glucagon — the "burn more" switch

This is the one that gets people excited.

GLP-1 and GIP help reduce food intake. Glucagon-receptor activity is meant to add effects on energy use and liver fat.

The idea: pull both levers at once and you should get more.

That's the theory. The rest of this page tests it.

A quick receptor map

Look at that table for a second. Tirzepatide and survodutide are both called dual agonists — but they don't share a single extra receptor beyond GLP-1. One adds GIP. The other adds glucagon. Calling them the same category is like calling a motorcycle and a pickup truck "two-axle vehicles." Technically true. Not useful.

Hold that thought.

Is retatrutide really "GLP-3"?

No. "GLP-3" is internet slang. There is no receptor called GLP-3 and no drug class by that name.

Lilly's own wording is "GIP, GLP-1, and glucagon triple hormone receptor agonist." If a website is selling you something called GLP-3, that tells you something about the website.

Two drugs people put in the wrong box

MariTide (Amgen) hits two targets — but it blocks GIP instead of turning it on. That's the opposite of what tirzepatide does. And people still lost weight on it in Phase 2. So it isn't just that the receptor count doesn't predict results. Even the direction of the second target is an open question.

CagriSema (Novo Nordisk) gets called a dual agonist all the time. It's really two separate molecules in one injection — semaglutide plus an amylin drug. Different hormone family, different page. (CagriSema status →)

---

Triple agonist vs dual agonist weight loss: does the triple win?

In separate trials, yes — retatrutide's average was higher than tirzepatide's. But the honest size of that gap is about 3 to 6 percentage points, not the 7 to 9 most articles report. The bigger number comes from comparing two trials that used different statistical methods.

This is the single most repeated mistake on this topic, and once you see it you can't unsee it.

These obesity trials report two numbers

Not one. Two. They answer different questions.

The "stayed on it" number (researchers call it the efficacy estimand). This estimates what the average would look like if everyone had kept taking the drug as assigned.

The "everyone counted" number (the treatment-regimen or treatment-policy estimand). This counts everybody who was assigned the drug — including people who stopped taking it, cut their dose, or started something else. The labels and models differ by trial, but these are the closest matched family of estimates.

In every trial used on this page, the second number is smaller. It includes more of what happens in real life because it counts people who stop or change treatment.

Now watch what happens.

Where the 7.4-point gap comes from

The RX Index calculations from two separate trials. Placebo subtraction is arithmetic within each trial, not a head-to-head treatment effect.

The 7.4-point version is everywhere. It's on clinic blogs, peptide shops, and a few large health sites. It compares retatrutide's continued-treatment number to tirzepatide's everyone-counted number.

When you match the method, the gap is roughly 3 to 6 points.

That's still a real edge. We're not saying retatrutide is unimpressive — it clearly did something. We're saying the edge is about half the size of what you were told.

What does a "point" mean for an actual person?

Say you weigh 250 pounds.

• 3 points ≈ 7.5 pounds of difference
• 6 points ≈ 15 pounds of difference

Meaningful. But not the 7-to-9-point blowout the headlines suggest. And it's the difference between a drug that can be prescribed now in the United States and a drug that isn't approved anywhere.

One thing a trial average is not

It's not a forecast for you.

Inside those averages, some people lost a lot more. Some lost far less. Some quit in month two. A trial average is a group result — it tells you what the drug tends to do across thousands of people, not what it will do in your body.

→ Use the Same-Ruler Translator — it converts the matched trial gaps into pounds at your starting weight.

Same-Ruler Translator

This converts published group-average gaps into pounds at a starting weight. It is arithmetic, not a forecast for you.

For any other starting weight, use: starting weight × gap ÷ 100.

These are differences between separate-trial averages after matching estimand families. They are not a prediction of what either drug will do for you.

---

Why "more receptors" doesn't predict more weight loss

Five drugs across six trial arms, measured on the same broad ruler, do not line up by receptor count. Two dual agonists that hit the identical pair of receptors came in 7.6 points apart. One dual agonist scored below both doses of a single-agonist drug. Receptor count is a biological description, not a ranking.

Most two-drug comparisons stop after retatrutide and tirzepatide. This table keeps going.

We pulled six drug-dose rows across five drugs. Same outcome, matched estimand family, each trial's own placebo result shown and subtracted.

The same-ruler table

"Everyone counted" family, placebo-adjusted:

"Stayed on it" method, placebo subtracted:

The RX Index calculations. Five separate trials, six drug-dose rows, different populations and lengths. The first table groups treatment-regimen and treatment-policy estimands; those labels and missing-data models are not identical. Sources are listed at the end of this page.

Now the three things that fall out of it.

Finding 1: Two drugs with the same two receptors, twice the gap

Survodutide and mazdutide both hit GLP-1 + glucagon. Same pair. Same category label. Both once-weekly shots.

• Mazdutide 9 mg: 15.2 points
• Survodutide 6.0 mg: 7.6 points

That's a 7.6-point spread inside a single category. On the same placebo-adjusted, everyone-counted ruler, the gap between the best triple and the best dual is 3.3 points.

The spread within "dual agonist" is more than double the spread between triple and dual.

Read that again, because it's the whole answer to the question you came here with. Two drugs pressing the exact same two buttons got results twice as far apart as three buttons versus two.

Finding 2: A dual agonist lost to a single agonist

Survodutide activates two receptors and showed a 7.6-point placebo-adjusted difference.

Semaglutide activates one receptor and showed an 11.7-point placebo-adjusted difference at 2.4 mg and 14.8 points at 7.2 mg.

More targets. Less weight loss. There goes "3 beats 2 beats 1."

Finding 3: It's not just weight — dropouts don't follow receptor count either

Important: these are three different measurements. Survodutide's counts stomach problems only. Retatrutide's counts everything. Tirzepatide's comes from its FDA label across two trials. Zepbound's own label states that side-effect rates from different trials can't be directly compared — and that warning applies to this table too.

Even with that mismatch, this table does not support a simple "fewer receptors means gentler" story: the two-receptor survodutide arm had the highest reported discontinuation figure. Fewer receptors did not mean gentler.

One more oddity worth knowing: in TRIUMPH-1, retatrutide's lowest dose (4 mg) had a 4.1% dropout rate for side effects — lower than its own placebo group at 4.9%. People on placebo quit more often than people on the low dose of the drug.

So what actually decides how much weight comes off?

Based on what these five trials and six drug-dose rows show, receptor count is far down the list. What appears to matter more:

• The specific molecule. Two GLP-1 + glucagon drugs, wildly different results.
• The dose. Semaglutide at 7.2 mg showed 3.1 more placebo-adjusted points than the same drug at 2.4 mg. Same receptor. Same molecule. Just more of it.
• How long the trial ran. 60 weeks to 80 weeks across this table.
• Who was in the trial. More on that below — it moves the number a lot.
• How many people stayed on it.

That's our read of the evidence, and we'll label it as exactly that: our conclusion, drawn from the numbers above, which you can check yourself.

---

Where our own math gets shaky

Cross-trial comparisons have a built-in weakness: the placebo groups aren't the same. Across these five trials, placebo groups lost anywhere from 1.5% to 5.4% of body weight — a 3.9-point spread that's wider than the difference between several of the drug-dose rows.

We're going to argue against our own table for a minute. You should know where it bends.

The placebo groups don't match

A placebo group is the within-trial baseline — the lifestyle program plus placebo instead of the active study drug. If one trial's baseline is nearly four times another's, subtracting it doesn't clean things up as much as you'd hope.

And there's a specific reason for the extreme one

The published SYNCHRONIZE-1 treatment-regimen analysis counted people who used other obesity medicines during the trial. Some placebo participants started another GLP-1 medication. That likely pushed the placebo group's weight loss up — which pulls survodutide's placebo-adjusted number down.

So is survodutide really that far behind? Probably not by the full amount our table shows. Its raw number, before any subtraction, was 13.0% to 16.6% depending on the method — respectable.

Does that undo Finding 1? No. Even using the raw, unsubtracted numbers, mazdutide (16.7% to 18.6%) still lands ahead of survodutide (13.0% to 16.6%) despite hitting the same two receptors — and both sit well below tirzepatide, which hits a different second receptor. The category still doesn't predict the result.

Why are we telling you this? Because a page that only shows you the math that supports its point isn't a research page. It's a sales page. You can check every number in our table against the sources at the bottom, including the ones that make our argument weaker.

---

What the 2026 retatrutide trials actually showed

Retatrutide's average result changed a lot depending on who was in the trial: 28.3% in general obesity without diabetes, 22.6% in severe obesity with heart disease, and 20.8% in people with type 2 diabetes. All three are company topline results — the detailed peer-reviewed publications are still pending.

The number you saw in a headline came from one specific trial with one specific group of people. Change the group, change the number.

Source: Eli Lilly topline releases, May 21 and July 23, 2026.

That's a 7.5-point swing across three trials of the same drug at the same dose. It is larger than the 3.3-point placebo-adjusted, everyone-counted gap between retatrutide and tirzepatide.

If you have type 2 diabetes, the 28.3% headline was never about you. The 20.8% one was. That pattern — people with diabetes losing less on the same drug — shows up in several major incretin trials.

About that 30.3% number

You may have seen "30.3%" reported as retatrutide's result. Here's what it actually is.

TRIUMPH-1 had a planned extension. It enrolled the first 532 participants who (a) finished all 80 weeks without quitting or permanently cutting their dose, (b) started with a BMI of 35 or higher, and (c) came from participating countries. They continued to 104 weeks.

That group reached 30.3%.

It's real data. It is not the same as the main result, because it only includes people who already tolerated the drug for 80 weeks. Anyone who stopped or permanently reduced the dose isn't in it. A number from a selected group that already tolerated 80 weeks is not the number for everyone.

Use 28.3% as the main-trial headline. Keep 30.3% attached to the selected extension group that tolerated treatment through week 80.

On heart protection

TRIUMPH-3 studied people with severe obesity and existing heart disease. It improved several risk markers — triglycerides, blood pressure, cholesterol.

But it did not show that retatrutide prevents heart attacks or strokes. The statistical results for heart events left open the possibility of no difference at all. Anyone telling you retatrutide is proven to protect your heart is ahead of the data.

---

Does the third receptor explain retatrutide's bigger number?

Adding glucagon-receptor activity is a reasonable explanation, but no human trial has separated out what that third receptor contributed on its own. Retatrutide and tirzepatide are different molecules studied in different trials, so the difference can't be assigned to "one extra receptor."

Almost every page on this topic states it as fact: the glucagon receptor is what drives the bigger number.

It might be. But nobody has proven it, and here's a finding that should make you suspicious.

The side effect everyone blames on glucagon

Dysesthesia is a strange skin sensation — burning, tingling, pins and needles, skin that feels sunburned when nothing touched it. It showed up in retatrutide's trials and got a lot of attention. The common explanation online: it's the glucagon receptor.

Then look at semaglutide, which doesn't touch the glucagon receptor at all.

A single-receptor drug at a high dose produced nearly twice the rate of a triple-receptor drug at its top dose.

Notice what else that table shows: the same molecule, semaglutide, went from 6.0% to 22.9% when the dose went up. In STEP UP, the rate rose sharply with dose even though receptor count did not change. That makes receptor count a poor explanation by itself.

We are not going to tell you what causes dysesthesia. Nothing published explains the mechanism, and we're not going to invent one. What we can say is that the popular explanation does not fit as a complete explanation.

What's fair to say, and what isn't

Won't the head-to-head trial settle the receptor question?

No — and this is a distinction worth understanding.

TRIUMPH-5 compares the two finished medicines against each other. That will give a much fairer comparison of the drugs. It still won't isolate the glucagon receptor from every other difference between two molecules: how tightly each binds, how long each lasts in the body, how the dose ladder works, how many people tolerate it.

Comparing two drugs and isolating one receptor are different experiments.

---

Are triple agonist side effects worse than dual agonist side effects?

Retatrutide's trials reported more stomach-related side effects and more dropouts than tirzepatide's trials, plus a skin-sensation side effect at 12.5%. But these come from separate studies, and retatrutide has no FDA label yet — so its final warnings, contraindications, and monitoring rules aren't written.

Separate trial observations — not a head-to-head safety comparison.

Different trials, different people, different rules for recording side effects. Read this as "here's what each trial reported," not "here's which drug is safer."

What this looks like in practice

Most of these are stomach problems, and most showed up while the dose was climbing. That's the pattern across this entire drug class. Many ease after the dose stops rising.

But the dropout numbers matter more than the nausea numbers. A drug you can't tolerate has an effectiveness of zero. Retatrutide's 11.3% dropout at its top dose versus 6.2% for tirzepatide is a raw difference of roughly one extra person in twenty, but it is not a head-to-head estimate.

The thing people forget about retatrutide's side effect list

Every number above came from a supervised clinical trial. Participants had a fixed dose schedule, medical monitoring, someone to call, and the option to slow down.

Retatrutide's own trial data shows how much that matters. In the earlier Phase 2 study, two groups ended up at the same 8 mg dose. The group that started at 2 mg reported nausea in 17%. The group that started at 4 mg reported nausea in 60%.

Same drug. Same final dose. Three and a half times the nausea, just from how fast they got there.

A vial bought online does not give you an FDA-reviewed schedule or trial-level monitoring.

What Zepbound's label actually says

Zepbound has an FDA-approved label, which means its risks are documented and its warnings are official. It carries a boxed warning about thyroid C-cell tumors seen in rats — whether that applies to humans is unknown. It's not for people with a personal or family history of medullary thyroid cancer or MEN 2.

Retatrutide has no label at all. Not "a clean label" — no label. Its final warnings and monitoring rules don't exist yet because the FDA hasn't reviewed it.

Full retatrutide side effect breakdown, by dose, across all five trials →

---

What people are actually trying to decide

These are real posts, quoted as examples of the decision people are wrestling with — not as evidence about how well any drug works. We don't publish treatment-result testimonials on this page, because on an unapproved drug, a personal success story functions as an efficacy claim. It isn't one.

"I started reading more about Reta … but I can't decide." — r/GLP1ResearchTalk

"My plan is to wait until it's FDA approved." — r/Mounjaro

"THIS IS THE DREAM TRIAL!" — r/Zepbound, reacting to the head-to-head study

That last one is telling. People are watching TRIUMPH-5 because they know cross-trial math isn't enough.

---

Can you get a triple agonist right now?

No. As of August 14, 2026, no triple agonist for weight management is approved by the FDA or any other regulator worldwide. Retatrutide cannot be prescribed or sold as a commercial medication, and the FDA states it cannot be used in compounding under federal law. The two verified medical access paths to authentic Lilly-made retatrutide are a qualifying Lilly-sponsored clinical trial and a limited clinician-led expanded-access request that Lilly agrees to supply. Expanded access is not a public signup or a way to buy the drug.

Let's clear this up completely, because it's where people get hurt.

What you can and can't get

Of the two categories in your search, only one has a product you can legally buy in the United States. It's the dual.

Brand indications differ: Zepbound, Wegovy, Wegovy HD, Wegovy pill, and Foundayo are approved for weight management. Mounjaro and Ozempic are approved for type 2 diabetes.

Can a compounding pharmacy make retatrutide?

No. The FDA states directly that retatrutide cannot be used in compounding under federal law.

This isn't a gray area or a loophole that a "good" pharmacy has found. FDA says retatrutide is not a component of an FDA-approved drug and cannot be used in compounding under federal law.

A compounded retatrutide product is not a cheaper version of the real thing. It is a product with no legal compounding path under current federal law.

What about "research use only" vials?

That label doesn't make a product safe for a person. It usually means the opposite — that it was never made, tested, or packaged for human use.

The label alone cannot confirm what's in it, how much is in it, whether it's sterile, or whether it matches the molecule used in Lilly's trials.

We're not going to tell you where to buy it, how to dose it, or how to spot a "reputable" seller. There isn't one.

August 2026 enforcement update

Lilly filed six new lawsuits on August 12, 2026 against US entities it accused of selling black-market retatrutide, and repeated that no retatrutide medicine has been approved for human use anywhere.

If you already have a product like this and you feel unwell, call Poison Control at 1-800-222-1222. Calls are free, confidential, and answered by poison experts 24/7. If someone has collapsed, had a seizure, is having trouble breathing, or cannot be awakened, call 911.

Does "application planned for early 2027" mean approval in 2027?

No, and this trips up a lot of people.

Lilly says it plans to submit its application to the FDA in the first quarter of 2027. That's the start of the review, not the end.

Here's the honest sequence: the company submits → the FDA has 60 days to decide whether to file it → the FDA sets a review goal, usually 6 months after filing for priority review or 10 months for standard review → the FDA approves it or sends a complete response letter.

Submission dates slip. Reviews take as long as they take. Anyone publishing a specific approval date for retatrutide is guessing. We won't.

Full breakdown of the legal access paths, including expanded access →

→ Check which legal treatment paths are open in your state — the tool matches you against what's actually available where you live.

---

Should you wait for a triple agonist or start a dual agonist now?

Waiting costs time you can count. It buys a benefit nobody has measured yet in a direct comparison. For most people who want treatment now, an FDA-approved option offers something an investigational drug can't: a label, a legal prescription, a dose plan, and a start date.

Here's our honest position, including the part that doesn't help us.

The admission

Zepbound does not give you the biggest number in the research. If the highest average trial result is your only priority and nothing else matters, retatrutide looks stronger on paper, and we're not going to pretend otherwise.

But because Zepbound skips the waiting, you get things retatrutide doesn't have yet: an FDA-reviewed label with documented risks, a legal prescription, a dose schedule that's been tested, a prescriber who can adjust it when you struggle, and a legal start date you can pursue now instead of some point after a filing that hasn't happened.

The measured edge is 3 to 6 points, from separate trials, on a drug you can't legally buy. Tirzepatide showed a 17.8-point placebo-adjusted difference on the everyone-counted ruler and can be prescribed now.

A smaller number you can actually get beats a bigger number you can't.

And if maximum weight loss genuinely is your situation — high BMI, serious weight-related conditions, other treatments already tried — you're not out of options, and shopping for a vial is not one of them. There are two verified doors: qualifying Lilly-sponsored clinical trials and a narrow expanded-access pathway that your treating doctor has to start. Both are explained here →

Find your situation

Will starting now lock you out later?

There's no approved switching protocol today, because retatrutide has no FDA label. Any future switch would depend on what that label says, your medical history, how you responded, and your clinician's judgment.

What we can say: nothing about starting an approved medication now creates a rule that stops you later. No such rule exists yet, in either direction.

We won't promise you'll be able to switch smoothly. Nobody can promise that. Anyone who does is making it up.

Should you stop your current medication to wait?

No. Not based on this page or any headline.

If you're on a prescription right now, that decision belongs to you and the clinician managing it. A drug that isn't approved is not a reason to stop one that is.

→ Get your personalized GLP-1 action plan — answer a few questions about your state, insurance, medication preference, and budget, and see which approved treatment paths actually fit.

---

Once you know you want an FDA-approved option, the next question is who prescribes it and what it costs.

Ro is the path we point most readers toward for brand-name GLP-1s. It carries Zepbound (tirzepatide) and Foundayo (orforglipron). For supported insurance medications, Ro's concierge checks coverage and handles prior-authorization paperwork — which matters, because with these medications the paperwork is often the real obstacle, not the prescription. Ro Body is $39 for the first month, then $74 to $149/month depending on the plan — the $74 rate requires a 12-month plan paid upfront. Medication is billed separately. (Pricing verified August 14, 2026.)

→ Check your Zepbound coverage and eligibility on Ro (affiliate link)

Want to choose your own clinician instead? Sesame Care (affiliate link) offers a broader brand-name lineup with individual provider selection. Our full Sesame review →

Provider-stated vs verified: current access details

Neither one fits? Compare every FDA-approved path side by side →

---

What will the head-to-head trial actually answer?

TRIUMPH-5 is the one study comparing retatrutide directly against tirzepatide in the same trial. It's a Phase 3 study of 800 adults with obesity, running about 89 weeks, and it's double-blind with no placebo group — everyone gets an active drug, and participants and study investigators do not know which one during the trial. It started November 1, 2024 and is scheduled to finish December 31, 2026.

Every comparison on this page — including ours — is arithmetic across trials that were never designed to be compared. One study fixes that.

TRIUMPH-5 at a glance

Trial registry record, verified August 14, 2026.

Sit with that for a second. Eight hundred people were assigned to one of these two drugs, and the blinded design keeps participants and study investigators from knowing which one during the trial. That's what double-blind means, and it's why the result will be worth far more than anything on this page.

There's no placebo arm at all. Everybody gets an active medication. That's a deliberate design choice for a head-to-head study.

What it will settle

• Same protocol, same entry rules, same measurement schedule for both drugs
• A real randomized comparison instead of subtraction across trials
• Side effects measured side by side in one population
• Dropout rates measured under identical conditions

What it won't settle

• It won't isolate the glucagon receptor from every other difference between the molecules
• It won't tell you anything about 5- or 10-year outcomes
• It won't guarantee FDA approval
• It won't determine price or insurance coverage
• It won't predict what happens in your body

One thing about that December date

"Scheduled completion" is when the study finishes collecting data. Public results come later — usually months later, often at a medical conference, then in a journal.

So December 31, 2026 is the date the clock runs out. It's not the date you'll read the answer. We check this record monthly and update the box above when it moves.

See the official record →

---

How we compared these drugs

We pulled results from FDA labels, peer-reviewed journals, trial registry records, and dated company releases. We matched estimand families before subtracting anything, kept separate trials clearly labeled as separate, and did not turn an observed difference into a claim about what caused it.

You should be able to check us. Here's exactly what we did.

Where our numbers came from, in order of weight

1. FDA approval records and prescribing information — the strongest source for an approved drug
2. Trial registry records — for design, size, dates, and status
3. Peer-reviewed published trials — SYNCHRONIZE-1 in NEJM, STEP UP in Lancet Diabetes & Endocrinology, GLORY-2 in JAMA
4. Official company topline releases — used where full publications don't exist yet, and always labeled "topline"
5. Provider websites — for current pricing only, with its own verification date
6. Forums and comments — for how people describe their decision. Never as medical evidence

The rules we followed

• Compare "stayed on it" to "stayed on it," and "everyone counted" to "everyone counted." Never mix them
• Show each trial's placebo group next to each drug's result
• Report differences in percentage points, never as "percent better"
• Keep trial length and population attached to every number
• Never combine separate trials into a pooled statistic without a proper method
• Never treat subtraction across trials as a head-to-head result
• Treat placebo subtraction as a within-trial arithmetic adjustment, not the drug's causal contribution
• Group treatment-regimen and treatment-policy estimates only as the closest "everyone counted" family; their exact models still differ
• Don't use the RX Index Score here — that framework scores telehealth providers on clinical legitimacy, care quality, transparency, access, and cost. It doesn't score medications

What our comparison can't do

We'd rather say this plainly than have you find it later:

• The main trials ran 60 to 80 weeks. Different lengths, different results
• Different sponsors, different sites, different rules for recording side effects
• Retatrutide's Phase 3 results are company toplines. Peer-reviewed detail is still pending
• The placebo groups varied by 3.9 points, which limits how clean any subtraction can be
• Trial averages are group results, not personal forecasts
• The direct comparison hasn't reported

Who made this and why

Who: Written and researched by Kaden, founder of The RX Index. No clinician has reviewed this page, and we don't claim one has.

How: We pulled every number into a structured sheet, checked how each trial defined its statistical methods, re-ran the arithmetic, and rechecked every time-sensitive fact on the verification date shown at the top.

Why: Because the most-repeated comparison on this topic — 28.3% versus 20.9% — puts two different statistical methods side by side and calls the result a winner. That's not a small technicality. It nearly doubles the apparent gap. Somebody should say so.

---

Frequently asked questions

A triple agonist is not automatically better than a dual agonist. Retatrutide's average was higher than tirzepatide's in separate trials, by roughly 3 to 6 percentage points when the estimand families are matched — but no triple agonist for weight management is approved anywhere, and receptor count does not predict results across the wider group of drugs.

Is Zepbound a dual agonist or a triple agonist?

Zepbound (tirzepatide) is a dual agonist. It activates the GIP and GLP-1 receptors. It does not activate the glucagon receptor.

Is there an FDA-approved triple agonist?

No. As of August 14, 2026, no triple agonist for weight management is approved by the FDA or any other regulator worldwide.

What is "GLP-3"?

Internet slang. There's no receptor called GLP-3 and no drug class by that name. Retatrutide is officially a GIP, GLP-1, and glucagon triple hormone receptor agonist. Sites selling "GLP-3" are usually selling unapproved product.

How much more weight loss did the triple agonist show?

About 5.8 percentage points when both trials' "stayed on it" numbers are compared, or 4.1 points using both "everyone counted" numbers. After subtracting each trial's placebo, the gaps are 6.0 points on the "stayed on it" ruler and 3.3 points on the "everyone counted" ruler. None of these is a head-to-head result.

Why do other websites say the difference is 7 or 8 points?

Because they compare retatrutide's 28.3% (its "stayed on it" number) against tirzepatide's 20.9% (its "everyone counted" number). Two different statistical questions. Matching the estimand family gives 5.8 or 4.1 points; the placebo-adjusted versions are 6.0 or 3.3 points.

Does a triple agonist always beat a dual agonist?

No. In our five-drug, six-arm comparison, one dual agonist — survodutide — showed a 7.6-point placebo-adjusted difference, less than semaglutide, a single-receptor drug, at either of its doses. Two dual agonists hitting the exact same receptor pair came in 7.6 points apart.

Can my doctor prescribe retatrutide?

No. It hasn't been approved, and Lilly states it can't legally be sold or marketed for human use. The two verified access paths are a qualifying Lilly-sponsored clinical trial and a narrow expanded-access request a treating physician must initiate.

Can retatrutide be compounded?

No. The FDA states retatrutide cannot be used in compounding under federal law.

When will retatrutide be FDA-approved?

No approval date exists. Lilly plans to submit its application in the first quarter of 2027. A submission is the beginning of an FDA review, not an approval, and review timelines vary.

Is retatrutide safer than Zepbound?

That can't be concluded. Zepbound has an FDA-reviewed label documenting its risks. Retatrutide has no label, so its final warnings and monitoring rules don't exist yet. In separate trials, retatrutide reported more stomach side effects and more dropouts.

Does retatrutide cause dysesthesia?

It occurred in its trials — 12.5% at the 12 mg dose in TRIUMPH-1, versus 0.9% on placebo. Notably, semaglutide 7.2 mg reported 22.9% in its own trial, so this side effect is not unique to triple agonists.

Can I switch from Zepbound to retatrutide later?

There's no approved switching protocol, because retatrutide has no FDA label. Any future switch would depend on approval, what that label says, and your clinician's judgment.

Should I stop my current GLP-1 and wait?

No. Not based on this page or any headline about an unapproved drug. That decision belongs with the clinician managing your prescription.

Will insurance cover retatrutide?

There are no commercial coverage terms because it isn't approved or sold as a prescription drug.

Is CagriSema a dual agonist?

Not in the sense this page uses. CagriSema combines semaglutide with an amylin medication — a different hormone family than GIP or glucagon.

What is TRIUMPH-5?

The one Phase 3 trial comparing retatrutide directly against tirzepatide. It includes 800 adults with obesity, is double-blind with no placebo group, is active but not recruiting, and is scheduled to finish December 31, 2026.

---

Still not sure which GLP-1 program is right for you?

Take our free 2-minute matching quiz. Answer a few questions about your state, your insurance, whether you want an FDA-approved medication or a compounded option that is not FDA-approved, injection or oral, and your budget. You'll get the treatment paths that actually fit — with pricing traced to the source.

→ Get my personalized action plan

Free. About two minutes. No signup.

---

Sources

1. Eli Lilly. "Lilly's triple agonist, retatrutide, delivered powerful weight loss in pivotal Phase 3 obesity trial." May 21, 2026. TRIUMPH-1, NCT05929066.
2. Eli Lilly. "Lilly's triple agonist, retatrutide, successful in two additional Phase 3 obesity trials." July 23, 2026. TRIUMPH-2, NCT05929079; TRIUMPH-3, NCT05882045.
3. Jastreboff AM, et al. "Tirzepatide Once Weekly for the Treatment of Obesity." New England Journal of Medicine. 2022. SURMOUNT-1, NCT04184622.
4. US Food and Drug Administration. Zepbound (tirzepatide) US prescribing information. Revised February 2026.
5. le Roux CW, et al. "Survodutide Once Weekly for the Treatment of Adults with Obesity." New England Journal of Medicine. June 7, 2026. SYNCHRONIZE-1, NCT06066515.
6. Boehringer Ingelheim. SYNCHRONIZE-1 Phase 3 data release. June 7, 2026.
7. Gao L, Jiang H, Cai H, et al. "Treatment With 9-mg Mazdutide for Weight Reduction in Chinese Adults With Obesity: The GLORY-2 Randomized Clinical Trial." JAMA. June 7, 2026. NCT06164873.
8. Innovent Biologics. GLORY-2 mazdutide 9 mg topline release. November 20, 2025.
9. Wharton S, et al. "Once-weekly semaglutide 7.2 mg in adults with obesity (STEP UP): a randomised, controlled, phase 3b trial." Lancet Diabetes & Endocrinology. 2025. NCT05646706.
10. US Food and Drug Administration. Wegovy (semaglutide) prescribing information. Revised 2026.
11. Jastreboff AM, et al. "Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial." New England Journal of Medicine. 2023;389:514-526.
12. Borner T, et al. "GIP Receptor Agonism Attenuates GLP-1 Receptor Agonist-Induced Nausea and Emesis in Preclinical Models." Diabetes. 2021.
13. US Food and Drug Administration. "FDA's Concerns with Unapproved GLP-1 Drugs Used for Weight Loss." Updated June 15, 2026.
14. ClinicalTrials.gov. TRIUMPH-5, NCT06662383. Retrieved August 14, 2026.
15. Eli Lilly. "Lilly calls on online platforms, payment companies and regulators to shut down the illegal retatrutide black market." August 12, 2026.
16. Eli Lilly. Expanded Access Policy. See also retatrutide expanded access, NCT07629401.
17. US Food and Drug Administration. "FDA Approves First New Molecular Entity Under National Priority Voucher Program." April 1, 2026. Foundayo (orforglipron).
18. Innovent Biologics. Mazdutide approval and development update. October 28, 2025.
19. Viking Therapeutics. VK2735 Phase 3 VANQUISH program update. July 29, 2026.
20. Novo Nordisk. Second-quarter 2026 R&D presentation: UBT251 global Phase 1b/2a development. August 4, 2026.
21. Amgen. "The Story of Maridebart Cafraglutide (MariTide)." May 2026.
22. Ro. Weight loss program pricing. Verified August 14, 2026.
23. Ro. Weight loss program and insurance. Verified August 14, 2026.
24. Sesame Care. Online weight loss program. Verified August 14, 2026.
25. Poison Control. Get immediate poison-exposure help. Verified August 14, 2026.

---

Change log

August 14, 2026 — Major rebuild. Replaced the TRIUMPH-4 vs SURMOUNT-5 comparison with TRIUMPH-1 vs SURMOUNT-1 using matched estimand families. Added TRIUMPH-2 and TRIUMPH-3. Added survodutide, mazdutide, and semaglutide at two doses to create the five-drug, six-arm same-ruler comparison. Relabeled placebo subtraction as a placebo-adjusted difference instead of a drug's causal contribution. Removed the claim that the glucagon receptor drives the difference, and added the dysesthesia comparison that does not fit that explanation. Corrected GLORY-2's registry number to NCT06164873, added Wegovy HD and Foundayo to the current-status table, clarified retatrutide's narrow expanded-access path, and corrected the regulatory timeline to a planned Q1 2027 application. Added the TRIUMPH-5 head-to-head record and the August 12, 2026 enforcement update. Replaced every placeholder URL with a live site route or source link.

We update this page monthly, and immediately when a trial reports or the FDA acts. The verification date at the top changes only when we've actually rechecked.